24 August 2018
Published by Oxford University Press on behalf of the Association of Physicians
Journal Issue: Q J Med 2015; 108:49–50
Authors: C.V. TONG1, Z. HUSSEIN1, N. MOHD NOOR1, M. MOHAMAD1 and W.F. NG1
Institutions: 1Department of Medicine, Endocrine Unit, Hospital Putrajaya, Pusat Pentadbiran Kerajaan Persekutuan, Presint 7, 62250 Putrajaya, Malaysia
Address correspondence to C.V. Tong, Department of Medicine, Endocrine Unit, Hospital Putrajaya, Pusat Pentadbiran Kerajaan Persekutuan, Presint 7, 62250 Putrajaya, Malaysia. email: firstname.lastname@example.org
Learning Point for Physicians
This case illustrates the difficulties in treating hypercalcemia caused by parathyroid carcinoma. However, there are various choices of treatment and in recalcitrant cases, denosumab should be considered as a therapeutic option. It is important to know the vitamin D status of the patient and to monitor for hypocalcemia post treatment.
Use of denosumab in parathyroid carcinoma with refractory hypercalcemia
Parathyroid carcinoma is rare; accounting for 1% of all the causes of primary hyperparathyroidism.1 When the tumor is no longer amenable for surgery, medical therapy to control the hypercalcemia becomes the main focus of management. Unfortunately, parathyroid carcinoma mediated hypercalcemia is often severe and more resistant to medical therapy. We report a case of parathyroid carcinoma with refractory hypercalcemia treated with denosumab.
Please read the full article here..
For more articles click here..